Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) is up 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The gain appears tied to a mix of fresh oncology-related momentum and a bullish analyst target increase. Recent presentations around Signatera at ESMO 2026 added to the company’s growth story in minimal residual disease testing, and that seems to have been reinforced by a higher Wall Street valuation.

Details:

Natera highlighted multiple ESMO 2026 presentations for its oncology portfolio, including bladder cancer data and broader evidence supporting Signatera in MRD-guided care.

The company said its technology was featured in 25 ESMO abstracts, including 9 oral presentations, which kept attention on its oncology pipeline and clinical utility.

A BTIG analyst raised the price target on Natera to $430 from $320 on October 27, giving traders a fresh bullish talking point heading into the new session.

Natera also recently announced that its Signatera MRD test was named to TIME’s Best Inventions of 2026 list, adding another positive headline around the platform.

Sources:

Natera Investor Relations, Benzinga, TIME

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NTRA Insider Trading Activity

$NTRA insiders have traded $NTRA stock on the open market 290 times in the past 6 months. Of those trades, 0 have been purchases and 290 have been sales.

Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:

MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 84 sales selling 315,157 shares for an estimated $95,982,307.
JONATHAN SHEENA has made 0 purchases and 96 sales selling 64,730 shares for an estimated $20,942,428.
ROELOF BOTHA has made 0 purchases and 6 sales selling 78,000 shares for an estimated $17,184,092.
DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 20 sales selling 52,951 shares for an estimated $13,672,432.
STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 26 sales selling 53,843 shares for an estimated $12,646,395.
SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 31 sales selling 37,841 shares for an estimated $11,137,832.
HERM ROSENMAN sold 16,530 shares for an estimated $4,132,500
JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 6 sales selling 10,254 shares for an estimated $2,966,387.
GAIL BOXER MARCUS has made 0 purchases and 4 sales selling 11,000 shares for an estimated $2,389,328.
MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 14 sales selling 9,724 shares for an estimated $2,259,437.
ROWAN E CHAPMAN has made 0 purchases and 2 sales selling 3,099 shares for an estimated $679,636.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive NTRA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$NTRA Hedge Fund Activity

We have seen 527 institutional investors add shares of $NTRA stock to their portfolio, and 317 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 12,865,346 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,492,298,171
PRICE T ROWE ASSOCIATES INC /MD/ removed 3,162,981 shares (-26.0%) from their portfolio in Q2 2026, for an estimated $858,591,192
FMR LLC added 2,897,142 shares (+113.4%) to their portfolio in Q2 2026, for an estimated $786,429,195
GOLDMAN SACHS GROUP INC added 952,921 shares (+124.2%) to their portfolio in Q2 2026, for an estimated $258,670,405
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 806,536 shares (+inf%) to their portfolio in Q2 2026, for an estimated $218,934,197
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 795,962 shares (+242.8%) to their portfolio in Q2 2026, for an estimated $216,063,884
WELLINGTON MANAGEMENT GROUP LLP removed 727,855 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $197,576,239

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NTRA Government Contracts

We have seen $791,200 of award payments to $NTRA over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

DNA TESTING: $230,000
TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $80,400

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$NTRA Analyst Ratings

Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/23/2026

To track analyst ratings and price targets for $NTRA, check out Quiver Quantitative's $NTRA forecast page.

$NTRA Price Targets

Multiple analysts have issued price targets for $NTRA recently. We have seen 11 analysts offer price targets for $NTRA in the last 6 months, with a median target of $275.0.

Here are some recent targets:

Tejas Savant from Morgan Stanley set a target price of $310.0 on 07/09/2026
Daniel Markowitz from Evercore ISI Group set a target price of $300.0 on 07/06/2026
Subbu Nambi from Guggenheim set a target price of $290.0 on 06/29/2026
Eve Burstein from Bernstein set a target price of $310.0 on 06/26/2026
Luke Sergott from Barclays set a target price of $260.0 on 06/24/2026
Mark Massaro from BTIG set a target price of $275.0 on 06/24/2026
Dan Leonard from RBC Capital set a target price of $275.0 on 06/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.